ADXN
Addex Therapeutics Ltd
Price Chart
Latest Quote
$7.66
Current Price| Previous Close | $7.66 |
| Open | $7.60 |
| Day High | $7.66 |
| Day Low | $7.66 |
| Volume | 464 |
Stock Information
Note: Financial values converted from CHF to USD
| Shares Outstanding | 1.23M |
| Total Debt | $47K |
| Cash Equivalents | $2.81M |
| Revenue | $204K |
| Net Income | $-7.96M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $9.44M |
| EPS (TTM) | $-9.31 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 24/42| Debt to Equity | 0.00 |
| Debt to Earnings | -0.01 |
| Current Ratio | 4.42 |
| Quick Ratio | 4.19 |
| Avg Revenue Growth | -21.54% |
| Profit Margin | 1746.04% |
| Return on Equity | 72.91% |
| Avg FCF Growth | -15.88% |
| FCF Yield | -56.95% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-01-30 | $7.66 | 1,700 |
| 2026-01-29 | $8.24 | 5,400 |
| 2026-01-28 | $7.78 | 5,000 |
| 2026-01-27 | $7.98 | 1,700 |
| 2026-01-26 | $7.63 | 1,200 |
| 2026-01-23 | $8.00 | 2,800 |
| 2026-01-22 | $8.00 | 3,400 |
| 2026-01-21 | $8.30 | 3,000 |
| 2026-01-20 | $8.23 | 11,000 |
| 2026-01-16 | $8.33 | 4,500 |
| 2026-01-15 | $8.10 | 1,400 |
| 2026-01-14 | $8.21 | 2,500 |
| 2026-01-13 | $8.80 | 112,100 |
| 2026-01-12 | $8.23 | 1,300 |
| 2026-01-09 | $7.80 | 1,300 |
| 2026-01-08 | $7.80 | 3,900 |
| 2026-01-07 | $7.94 | 8,700 |
| 2026-01-06 | $8.09 | 0 |
| 2026-01-05 | $8.09 | 1,400 |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
đ° Latest News
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst ...
GuruFocus.com âĸ 2025-12-04T23:06:42Z
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...
GuruFocus.com âĸ 2025-10-01T21:01:16Z
European Market Insights: Addex Therapeutics Among 3 Promising Penny Stocks
Simply Wall St. âĸ 2025-09-15T11:05:10Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $404,102 | $1,612,953 | $1,422,438 | $2,916,308 |
| Operating Revenue | $404,102 | $1,612,953 | $1,422,438 | $2,916,308 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $3,547 | $3,865 | $27,946 | $63,012 |
| Total Expenses | $3,159,335 | $3,855,920 | $11,963,339 | $18,422,222 |
| Other Income Expense | $-2,159,727 | $-317,285 | $-264,360 | $211,693 |
| Net Non Operating Interest Income Expense | $5,618 | $60,099 | $1,305 | $-57,690 |
| Interest Expense Non Operating | $3,547 | $3,865 | $27,946 | $63,012 |
| Operating Expense | $3,159,335 | $3,855,920 | $11,963,339 | $18,422,222 |
| Other Operating Expenses | $856,272 | $870,493 | $808,979 | $1,314,260 |
| General And Administrative Expense | $1,675,176 | $2,030,961 | $3,262,024 | $7,746,266 |
| Rent Expense Supplemental | - | $35,567 | $47,283 | $37,512 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-4,909,342 | $-2,500,153 | $-10,803,956 | $-15,351,914 |
| Net Interest Income | $5,618 | $60,099 | $1,305 | $-57,690 |
| Interest Income | $9,165 | $63,964 | $29,251 | $5,322 |
| Normalized Income | $-4,926,772 | $-2,182,868 | $-10,539,596 | $-15,563,607 |
| Net Income From Continuing And Discontinued Operation | $7,055,787 | $-10,556,227 | $-20,804,213 | $-15,351,914 |
| Total Operating Income As Reported | $-2,755,233 | $-2,242,967 | $-10,540,901 | $-15,505,917 |
| Net Income Common Stockholders | $7,055,787 | $-10,556,227 | $-20,804,213 | $-15,351,914 |
| Net Income | $7,055,787 | $-10,556,227 | $-20,804,213 | $-15,351,914 |
| Net Income Including Noncontrolling Interests | $7,055,787 | $-10,556,227 | $-20,804,213 | $-15,351,914 |
| Net Income Discontinuous Operations | $11,965,129 | $-8,056,074 | $-10,000,257 | - |
| Net Income Continuous Operations | $-4,909,342 | $-2,500,153 | $-10,803,956 | $-15,351,914 |
| Pretax Income | $-4,909,342 | $-2,500,153 | $-10,803,956 | $-15,351,914 |
| Earnings From Equity Interest | $-2,177,157 | $0 | $0 | - |
| Interest Income Non Operating | $9,165 | $63,964 | $29,251 | $5,322 |
| Operating Income | $-2,755,233 | $-2,242,967 | $-10,540,901 | $-15,505,914 |
| Depreciation Amortization Depletion Income Statement | $192,698 | $11,752 | $8,814 | $347,613 |
| Depreciation And Amortization In Income Statement | $192,698 | $11,752 | $8,814 | $347,613 |
| Depreciation Income Statement | $192,698 | $11,752 | $8,814 | $347,613 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $8.40 | $-16.80 | $-55.20 | $-54.00 |
| Basic EPS | $8.40 | $-16.80 | $-55.20 | $-54.00 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,663,105 | $-1,873,051 | $-10,188,506 | $-15,152,982 |
| Total Unusual Items | $17,430 | $-317,285 | $-264,360 | $211,693 |
| Total Unusual Items Excluding Goodwill | $17,430 | $-317,285 | $-264,360 | $211,693 |
| Reconciled Depreciation | $260,120 | $305,952 | $323,144 | $347,613 |
| EBITDA (Bullshit earnings) | $-4,645,675 | $-2,190,336 | $-10,452,866 | $-14,941,289 |
| EBIT | $-4,905,795 | $-2,496,288 | $-10,776,010 | $-15,288,902 |
| Diluted Average Shares | $1,397,132 | $1,234,421 | $685,300 | $284,331 |
| Basic Average Shares | $817,607 | $619,230 | $376,541 | $284,331 |
| Diluted NI Availto Com Stockholders | $7,055,787 | $-10,556,227 | $-20,804,213 | $-15,351,914 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $17,430 | $-317,285 | $-264,360 | $211,693 |
| Research And Development | $435,189 | $942,714 | $7,883,522 | $9,014,083 |
| Selling General And Administration | $1,675,176 | $2,030,961 | $3,262,024 | $7,746,266 |
| Other Gand A | $1,206,813 | $1,163,839 | $1,417,707 | $1,379,734 |
| Insurance And Claims | $225,772 | $628,595 | $1,591,231 | $1,591,882 |
| Salaries And Wages | $242,591 | $238,527 | $253,086 | $4,737,138 |
| Rent And Landing Fees | - | $35,567 | $47,283 | $37,512 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $9,677,271 | $1,145,465 | $4,912,911 | $16,931,100 |
| Total Assets | $10,678,303 | $4,641,885 | $8,282,050 | $22,541,784 |
| Total Non Current Assets | $7,136,940 | $407,280 | $453,089 | $600,008 |
| Non Current Prepaid Assets | $7,089 | $54,344 | $54,355 | $57,908 |
| Current Assets | $3,541,363 | $4,234,605 | $7,828,961 | $21,941,776 |
| Other Current Assets | $7,967 | - | - | - |
| Prepaid Assets | $169,649 | $217,008 | $270,394 | $1,115,374 |
| Receivables | $15,513 | $151,268 | $598,316 | $324,421 |
| Accounts Receivable | $15,513 | $110,361 | $416,875 | $164,785 |
| Cash Cash Equivalents And Short Term Investments | $3,348,234 | $3,866,329 | $6,960,251 | $20,501,981 |
| Cash And Cash Equivalents | $3,341,738 | $3,865,481 | $6,957,086 | $20,484,836 |
| Cash Financial | $3,341,738 | $3,865,481 | $6,957,086 | $20,484,836 |
| Other Receivables | - | $40,907 | $181,441 | $159,636 |
| Current Deferred Assets | - | - | - | $0 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $41,994 | $344,336 | $373,135 | $482,014 |
| Long Term Debt And Capital Lease Obligation | $34,688 | $70,380 | $87,028 | $194,316 |
| Current Debt And Capital Lease Obligation | $7,306 | $273,956 | $286,107 | $287,698 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $1,001,032 | $3,496,420 | $3,369,139 | $5,610,684 |
| Total Non Current Liabilities Net Minority Interest | $198,939 | $603,136 | $87,028 | $1,475,841 |
| Non Current Deferred Liabilities | $0 | $89,232 | $0 | - |
| Current Liabilities | $802,093 | $2,893,284 | $3,282,111 | $4,134,843 |
| Current Deferred Liabilities | $0 | $234,978 | $0 | $0 |
| Payables And Accrued Expenses | $794,787 | $2,384,350 | $2,996,004 | $3,847,145 |
| Payables | $275,939 | $1,148,993 | $1,397,421 | $1,990,575 |
| Total Tax Payable | $22,649 | $164,609 | $120,875 | $203,288 |
| Accounts Payable | $253,290 | $984,384 | $1,276,546 | $1,787,287 |
| Other Payable | - | - | $120,875 | $203,288 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $9,677,271 | $1,145,465 | $4,912,911 | $16,931,100 |
| Total Equity Gross Minority Interest | $9,677,271 | $1,145,465 | $4,912,911 | $16,931,100 |
| Stockholders Equity | $9,677,271 | $1,145,465 | $4,912,911 | $16,931,100 |
| Other Equity Interest | $64,620,223 | $64,620,223 | $64,620,223 | - |
| Gains Losses Not Affecting Retained Earnings | $31,062,996 | $29,814,816 | $25,768,373 | $24,437,868 |
| Other Equity Adjustments | $31,062,996 | $29,814,816 | $25,768,373 | $24,437,868 |
| Retained Earnings | $-353,362,455 | $-360,418,242 | $-349,862,015 | $-329,057,802 |
| Long Term Equity Investment | $7,087,142 | $0 | - | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $56,061,527 | $59,159,103 | $38,214,291 | $11,374,803 |
| Ordinary Shares Number | $128,292,969 | $125,195,393 | $77,134,020 | $37,898,149 |
| Share Issued | $184,354,496 | $184,354,496 | $115,348,311 | $49,272,952 |
| Tangible Book Value | $9,677,271 | $1,145,465 | $4,912,911 | $16,931,100 |
| Invested Capital | $9,677,271 | $1,145,465 | $4,912,911 | $16,931,100 |
| Working Capital | $2,739,270 | $1,341,321 | $4,546,850 | $17,806,933 |
| Capital Lease Obligations | $41,994 | $344,336 | $373,135 | $482,014 |
| Total Capitalization | $9,677,271 | $1,145,465 | $4,912,911 | $16,931,100 |
| Treasury Stock | $869,708 | $909,566 | $6,278,763 | $11,703,279 |
| Additional Paid In Capital | $266,382,670 | $266,194,689 | $269,511,610 | $283,981,361 |
| Capital Stock | $1,843,545 | $1,843,545 | $1,153,483 | $49,272,952 |
| Common Stock | $1,843,545 | $1,843,545 | $1,153,483 | $49,272,952 |
| Employee Benefits | $164,251 | $443,524 | $0 | $1,281,525 |
| Non Current Pension And Other Postretirement Benefit Plans | $164,251 | $443,524 | $0 | $1,281,525 |
| Non Current Deferred Revenue | $0 | $89,232 | $0 | - |
| Long Term Capital Lease Obligation | $34,688 | $70,380 | $87,028 | $194,316 |
| Current Deferred Revenue | $0 | $234,978 | $0 | $0 |
| Current Capital Lease Obligation | $7,306 | $273,956 | $286,107 | $287,698 |
| Current Accrued Expenses | $518,848 | $1,235,357 | $1,598,583 | $1,856,570 |
| Investments And Advances | $7,087,142 | $0 | - | - |
| Investmentsin Associatesat Cost | $7,087,142 | $0 | - | - |
| Net PPE | $42,709 | $352,936 | $398,734 | $542,100 |
| Accumulated Depreciation | $-153,708 | $-4,321,748 | $-4,015,796 | $-3,773,870 |
| Gross PPE | $196,417 | $4,674,684 | $4,414,530 | $4,315,970 |
| Leases | $111,642 | $1,725,162 | $1,471,850 | $1,298,569 |
| Other Properties | $84,775 | $2,941,958 | $2,935,116 | $3,009,837 |
| Machinery Furniture Equipment | $0 | $7,564 | $7,564 | $7,564 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $6,496 | $848 | $3,165 | $17,145 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-5,374,827 | $-7,999,253 | $-16,437,766 | $-14,736,734 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-5,373,554 | $-7,992,411 | $-16,437,185 | $-14,705,185 |
| Cash Flow From Continuing Operating Activities | $-5,373,554 | $-7,992,411 | $-16,437,185 | $-14,705,185 |
| Operating Gains Losses | $-11,861,657 | $-62,643 | $-11,393 | $-150,464 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-1,273 | $-6,842 | $-581 | $-31,549 |
| Investing Cash Flow | $4,645,211 | $-6,842 | $2,972 | $-30,313 |
| Cash Flow From Continuing Investing Activities | $4,645,211 | $-6,842 | $2,972 | $-30,313 |
| Net Other Investing Changes | $5,119,754 | - | - | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-1,764 | $-8,948 | $-3,487 | $-332 |
| Issuance Of Capital Stock | $240,899 | $2,350,512 | $1,675,866 | $13,958,189 |
| Financing Cash Flow | $104,918 | $5,264,596 | $3,102,688 | $16,402,824 |
| Cash Flow From Continuing Financing Activities | $104,918 | $5,264,596 | $3,102,688 | $16,402,824 |
| Net Other Financing Charges | $-14,853 | $-28,739 | $-523,112 | $-2,652,545 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $239,135 | $2,341,564 | $1,672,379 | $13,957,857 |
| Common Stock Issuance | $240,899 | $2,350,512 | $1,675,866 | $13,958,189 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-73,688 | $-281,793 | $-288,076 | $-309,617 |
| End Cash Position | $3,341,738 | $3,865,481 | $6,957,086 | $20,484,836 |
| Beginning Cash Position | $3,865,481 | $6,957,086 | $20,484,836 | $18,695,040 |
| Effect Of Exchange Rate Changes | $99,682 | $-356,948 | $-196,225 | $122,470 |
| Changes In Cash | $-623,425 | $-2,734,657 | $-13,331,525 | $1,667,326 |
| Interest Paid Cff | $-9,219 | $-21,607 | $-48,897 | $-63,012 |
| Proceeds From Stock Option Exercised | $-36,457 | $3,255,171 | $2,290,394 | $5,470,141 |
| Common Stock Payments | $-1,764 | $-8,948 | $-3,487 | $-332 |
| Net Issuance Payments Of Debt | $-73,688 | $-281,793 | $-288,076 | $-309,617 |
| Net Long Term Debt Issuance | $-73,688 | $-281,793 | $-288,076 | $-309,617 |
| Long Term Debt Payments | $-73,688 | $-281,793 | $-288,076 | $-309,617 |
| Net Investment Purchase And Sale | $0 | $0 | $3,553 | $1,236 |
| Sale Of Investment | $0 | $0 | $3,553 | $1,236 |
| Net Business Purchase And Sale | $-473,270 | $0 | $0 | - |
| Purchase Of Business | $-473,270 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-1,273 | $-6,842 | $-581 | $-31,549 |
| Purchase Of PPE | $-1,273 | $-6,842 | $-581 | $-31,549 |
| Change In Working Capital | $-1,228,370 | $213,756 | $157,677 | $-761,567 |
| Change In Other Working Capital | $-38,401 | $324,210 | - | $-820,149 |
| Change In Other Current Assets | $-13,615 | $2,317 | $13,980 | $47,785 |
| Change In Payables And Accrued Expense | $-1,146,084 | $-613,205 | $-427,388 | $883,837 |
| Change In Prepaid Assets | $-164,284 | $53,386 | $844,980 | $-616,992 |
| Change In Receivables | $134,014 | $447,048 | $-273,895 | $-256,048 |
| Changes In Account Receivables | $93,107 | $306,514 | $-252,090 | $-96,412 |
| Other Non Cash Items | $400,566 | $2,106,751 | $3,897,600 | $1,211,147 |
| Depreciation Amortization Depletion | $260,120 | $305,952 | $323,144 | $347,613 |
| Depreciation And Amortization | $260,120 | $305,952 | $323,144 | $347,613 |
| Depreciation | $260,120 | $305,952 | $323,144 | $347,613 |
| Pension And Employee Benefit Expense | $-95,219 | $-62,643 | $-11,393 | $-150,464 |
| Earnings Losses From Equity Investments | $2,177,157 | $0 | $0 | - |
| Gain Loss On Sale Of Business | $-13,943,595 | $0 | $0 | - |
| Net Income From Continuing Operations | $7,055,787 | $-10,556,227 | $-20,804,213 | $-15,351,914 |
| Stock Based Compensation | - | - | $3,682,073 | $1,178,344 |
| Gain Loss On Sale Of PPE | - | - | $0 | $-127 |